12 News & Press Releases found
AOBiome Therapeutic, LLC News
-
AOBiome Therapeutics Announces Appointment of Dr. Judith Ng Cashin as Chief Medical Officer
AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today ...
-
AOBiome’s B244 demonstrated positive results from its Phase 2b trial for both Pruritus (Itch) and Appearance of Atopic Dermatitis (Eczema)
B244 reduced patients’ WI-NRS score by an average of 34.3% and achieved clinically meaningful 4-point itch response Lesional severity (appearance) improved for IGA and EASI Results were achieved in 4 weeks Safe and well tolerated with no ...
-
AOBiome Achieves Landmark Recruitment Goal in Largest Clinical Trial Ever Powered by a Live Topical Biotherapeutic
AOBiome Therapeutics), a leading clinical-stage biotechnology company focusing on inflammation, announced completion of enrollment in its Phase 2b clinical trial in pruritus (itch) associated with atopic dermatitis. This trial is based on previous ...
-
AOBiome`s 30 Patient Study Using New Shelf-Stable Formulation of its Ammonia Oxidizing Bacteria (AOB) Shows Significant Reduction of Itch Levels in Both Pediatric and Adult Subjects who Suffer from Eczema
Newly completed study aimed to understand the safety and potential benefits of the AOB’s cellular structure without the production of nitric oxide and nitrite. CAMBRIDGE, Mass., Aug. 17, 2021 /PRNewswire/ — AOBiome Therapeutics, Inc. ...
-
Nature Scientific Reports has published a peer reviewed paper showing important immune response benefits associated with AOBiome`s B244 Ammonia Oxidizing Bacteria drug therapy
B244 inhibits Th2 immune polarization in human primary immune cells in both the active and the inactive state. CAMBRIDGE, Mass., July 15, 2021 /PRNewswire/ — AOBiome Therapeutics, Inc. (“AOBiome”), a leading clinical-stage ...
-
AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults
AOBiome’s 576 patient Phase 2b trial commences patient enrollment CAMBRIDGE, Mass., June 30, 20120/PRNewswire/ -- AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage microbiome company focusing on inflammation, ...
-
AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults
AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage microbiome company focusing on inflammation, announced initiation of a Phase 2b clinical trial in pruritus (itch) associated with atopic dermatitis based on positive clinical ...
-
AOBiome Featured in Bloomberg Businessweek
It was a snowy week in February 2009 when David Whitlock packed up his three-bedroom apartment near Cambridge, Mass., and moved into his van. Then 54 years old, the inventor had spent all his money, almost half a million dollars, on worldwide patent ...
-
AOBiome Doses First Patient in Phase 1b Clinical Trial of B244 for the Treatment of Pediatric Atopic Dermatitis
AOBiome Therapeutics, Inc. (“AOBiome”), a leading clinical-stage microbiome company focusing on the research and development of therapeutics for dermatological conditions, migraine, hypertension and other systemic diseases, today ...
-
AOBiome Therapeutics Expands Intellectual Property Estate with Issuance of U.S. Patent for Use of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Eczema
AOBiome Therapeutics, Inc. (“AOBiome”), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic ...
-
AOBiome Therapeutics Announces the Expansion of its Board of Directors
AOBiome Therapeutics, Inc. ("AOBiome"), a world-leading clinical-stage microbiome company focusing on research and development of therapeutics for inflammatory conditions, central nervous system disorders and other systemic diseases, today announced ...
-
AOBiome Therapeutics Announces Election of Dr. Jun Wang as Chairman of the Board of Directors
AOBiome Therapeutics ("AOBiome"), a world-leading clinical-stage microbiome company focusing on research and development of therapeutics for inflammatory conditions, central nervous system disorders and other systemic diseases, today announced the ...